Palvella Therapeutics, Inc. share price logo

Palvella Therapeutics, Inc. Share Price

NASDAQ: PVLA

Large Cap

$81.00

+0.50

(+0.63%)

Live

as on

Palvella Therapeutics, Inc. Stock Performance

as on November 14, 2025 at 8:39 pm IST

  • Day's Low

    Day's High

    $79.61
    $82.22
    downward going graph

    1.72%

    Downside

    1.51%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $11.17
    $85.03
    downward going graph

    86.21%

    Downside

    4.98%

    Upside

    downward going graph

Palvella Therapeutics, Inc. share price movements today

Previous Close
$80.50
Open
$79.62
Volume
42.4K
Day's Low - High
$79.61 - $82.22
52 Week Low - High
$11.17 - $85.03

Palvella Therapeutics, Inc. Historical Returns

1 Month Return
+ 9.49 %
3 Month Return
+ 74.62 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Palvella Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Palvella Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$965.1M

EPS (TTM)

-3.5783

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-301.19%

Palvella Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Palvella Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Palvella Therapeutics, Inc. image
Palvella Therapeutics, Inc.
NA$965.1MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$59.8B235.01%1414.811.36%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$40.9BNA712.211.38%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$110.2B92.67%30.5831.35%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$71.6B22.7%16.3432.13%

Palvella Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Palvella Therapeutics, Inc. Stock has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-24% versus previous 30 day period

Palvella Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Mar 2025
Jun 2025
Total Revenue
20
19
1
0
-
-
-
Gross Profit
19
18
1
-
-
-
-
Operating Income
2
3
-5
-1
-4
-7
-9
EBITDA
4
-10
-4
-1
-3
-6
-8
Interest Expense
-
-
-
0
1
1
1
Depreciation
-
-
-
-
-
-
-
Income Before Tax
3
-10
-4
-2
-3
-8
-9
Income Tax Expense
-
-
-
-
-
-
-
Net Income
3
-10
-4
-2
-3
-8
-9
Net Profit Margin
19.83%
-55.08%
-352.89%
-4784.91%
0.00%
0.00%
0.00%

Palvella Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
2
5
25
29
46
29
31
25
-
-
Gross Profit
-
-
-
-
-
29
29
23
-
-
Operating Income
-13
-22
-14
-30
-27
-33
-51
-43
-11
-14
EBITDA
-13
-22
-16
-26
-24
-34
-43
-30
18
-13
Interest Expense
-
-
-
-
-
-
-
-
-
4
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-13
-22
-16
-27
-25
-37
-45
-33
18
-17
Income Tax Expense
0
0
1
0
-
0
-
-1
-
-
Net Income
-14
-22
-17
-26
-25
-37
-45
-33
18
-17
Net Profit Margin
-479.50%
-391.00%
-69.82%
-91.93%
-55.03%
-126.97%
-145.58%
-128.47%
0.00%
0.00%

Palvella Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-10
-4
-2
-4
-6
-8
-9
-11
Operating Cash Flow
-9
-19
-1
-1
11
-6
-5
-7
Investing Cash Flow
-1
3
-
-
-3
-
-
-
Financing Cash Flow
-
0
-
9
77
-1
0
0
Change in Cash
-12
-15
-1
8
63
-7
-5
-6

Palvella Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-45
-27
18
-17
Operating Cash Flow
-7
-14
-13
-10
Investing Cash Flow
0
-21
-
-
Financing Cash Flow
59
9
5
87
Change in Cash
47
-5
-8
76

Insights on Palvella Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, PVLA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, PVLA stock has moved up by 74.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 81.5% return, outperforming this stock by 80.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 5 quarters, -2.88M → -11.34M (in $), with an average decrease of 44.9% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 20.05M → 53.0K (in $), with an average decrease of 64.0% per quarter

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
OrganisationPalvella Therapeutics, Inc.
Headquarters125 Strafford Avenue, Wayne, PA, United States, 19087
CEOMr. Wesley H. Kaupinen
E-voting on sharesClick here to vote

Key Management of Palvella Therapeutics, Inc.

Name

Title

Mr. Jason Burdette

SVP of CMC & Technical Operations

Ms. Kathleen Goin

Chief Operating Officer

Dr. Jeffrey Martini Ph.D.

Chief Scientific Officer

Mr. Matthew E. Korenberg

CFO & Treasurer

Ms. Emily Cook

Senior Vice President of Clinical Operations

Mr. Wesley H. Kaupinen

Founder, President, CEO & Director

Ms. Bohan Wei

Vice President of Corporate Development & New Product Planning

Ms. Ashley Kline

Chief Commercial Officer

Dr. David W. Osborne Ph.D.

Chief Innovation Officer

FAQs

What is Palvella Therapeutics, Inc. share price today?

Palvella Therapeutics, Inc. share price today is $81 as on . Palvella Therapeutics, Inc. share today touched a day high of $82.22 and a low of $79.61.

What is the 52 week high and 52 week low for Palvella Therapeutics, Inc. share?

Palvella Therapeutics, Inc. share touched a 52 week high of $85.03 on and a 52 week low of $11.17 on . Palvella Therapeutics, Inc. stock price today i.e. is trending at $81,which is 4.74% down from its 52 week high and 625.16% up from its 52 week low.

What is Palvella Therapeutics, Inc.'s market capitalisation today?

Palvella Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Palvella Therapeutics, Inc. Stock (PVLA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Palvella Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Palvella Therapeutics, Inc. Shares that will get you 0.0185 shares as per Palvella Therapeutics, Inc. share price of $81 per share as on November 14, 2025 at 8:39 pm IST.

What is the minimum amount required to buy Palvella Therapeutics, Inc. Stock (PVLA) from India?

Indian investors can start investing in Palvella Therapeutics, Inc. (PVLA) shares with as little as ₹88.7 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.00 in Palvella Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Palvella Therapeutics, Inc. share’s latest price of $81 as on November 14, 2025 at 8:39 pm IST, you will get 0.1235 shares of Palvella Therapeutics, Inc.. Learn more about fractional shares .